Agilent Technologies Inc. Introduces OneSeq To Streamline Cytogenetic Research
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) today introduced OneSeq, the industry’s first all-in-one target enrichment product for next-generation sequencing. OneSeq is designed to detect and analyze copy number variations, loss of heterozygosity, and mutations in a single reaction for use in constitutional disease research.
Agilent is showcasing the new product at the annual Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida, this week.
Powered by Agilent’s industry-leading SureSelect target-enrichment platform, the new OneSeq constitutional research panel will help laboratories involved in cytogenetic research save time gathering and analyzing complex, multifactorial data.
Help employers find you! Check out all the jobs and post your resume.
Agilent is showcasing the new product at the annual Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida, this week.
Powered by Agilent’s industry-leading SureSelect target-enrichment platform, the new OneSeq constitutional research panel will help laboratories involved in cytogenetic research save time gathering and analyzing complex, multifactorial data.
Help employers find you! Check out all the jobs and post your resume.